Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Internal Medicine
•
Hematology
•
MGUS
Do you perform biomarker-based screening for AL amyloidosis in patients with newly diagnosed MGUS?
If so, what is your approach to laboratory and clinical testing?
Answer from: Medical Oncologist at Academic Institution
No, unless the patient has signs and symptoms or imaging studies that suggest systemic Amyloidosis.
Sign in or Register to read more
6586
Related Questions
For otherwise transplant-eligible patients with myeloma, given developments of bispecifics and CAR-T, what is your age cutoff for consolidative autologous transplant?
How do you monitor multiple myeloma in patients receiving dialysis?
How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?
How do you utilize immunoglobulin testing to affect treatment decisions in patients with myeloma?
How do you discuss harms of MGUS screening with other medical providers?
In a patient with history of recurrent VTE despite anticoagulation, would you consider lenalidomide as part of your initial myeloma regimen?
How do you approach second-line options for relapsed myeloma after front-line quadruplet therapy?
Is there a role for CRS prophylaxis with tocilizumab during bispecific T cell engager initiation for myeloma?
With the recent approvals of CAR-T for second-line therapy in myeloma, does this change your approach to use of consolidative autologous transplant or autologous transplant as second line therapy?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?